Oculis Holding AG (NASDAQ:OCS) Receives $43.86 Average Target Price from Brokerages

Oculis Holding AG (NASDAQ:OCS) has received an average recommendation of “Moderate Buy” from the eight research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $43.8571.

A number of brokerages have issued reports on OCS. HC Wainwright increased their target price on shares of Oculis from $42.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Wall Street Zen cut Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Needham & Company LLC raised their price objective on Oculis from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. JPMorgan Chase & Co. started coverage on Oculis in a report on Friday, December 19th. They issued an “overweight” rating and a $38.00 price target for the company. Finally, Lifesci Capital began coverage on Oculis in a research report on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 price objective on the stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OCS. Gildi lifeyrissjodur acquired a new stake in shares of Oculis during the 4th quarter worth about $50,250,000. Aberdeen Group plc grew its holdings in shares of Oculis by 39.4% during the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after buying an additional 493,827 shares in the last quarter. SR One Capital Management LP raised its position in shares of Oculis by 98.8% in the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock valued at $12,801,000 after buying an additional 318,522 shares during the last quarter. Perceptive Advisors LLC purchased a new position in shares of Oculis during the fourth quarter valued at approximately $9,862,000. Finally, Alyeska Investment Group L.P. lifted its stake in shares of Oculis by 152.3% during the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after buying an additional 200,000 shares during the period. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Oculis Stock Performance

NASDAQ:OCS opened at $24.69 on Friday. The firm’s fifty day simple moving average is $27.43 and its 200-day simple moving average is $22.54. The company has a quick ratio of 5.96, a current ratio of 5.96 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.43 billion, a PE ratio of -10.88 and a beta of 0.29. Oculis has a fifty-two week low of $14.00 and a fifty-two week high of $30.68.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.08). The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.14 million. Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. Analysts expect that Oculis will post -2.09 earnings per share for the current fiscal year.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.